Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Jaclyn Carberry

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)

Professor T. Marwick (Melbourne, AU)

Presentation thumbnail

Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial

Associate Professor S. Prabhu (Melbourne, AU)

Presentation thumbnail

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

Doctor C. Chin (Singapore, SG)

Presentation thumbnail

Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.

Doctor Y. Hsu (Tainan, TW)

Access the full session

Session thumbnail

Smaller trials: cardiac function and remodelling

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Left ventricular reverse remodeling in heart failure with reduced ejection fraction: determinants and outcomes in a multidisciplinary heart failure clinic in a resource limited setting

Congress Presentation

New paradigms in pathological mechanosensing

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources